In the course of our systematic search for microbial metabolites effective against experimental tumors, an unusual Gram-negative bacterial strain No. K481-B101 (ATCC 53080), which was designated as Polyangium brachysporum sp. nov., was found to produce a complex of novel antitumor antibiotics1>2). They were recovered from the fermentation broth by extraction with organic solvent and purified by a series of chromatographies to yield three components, glidobactins A, B and C. As described in the following paper, structural studies demonstrated that glidobactins A, B and C are acylated cyclic tripeptides hitherto unobserved in nature3). This paper presents the production, isolation, chemical properties and biological activity of glidobactins A, B and C. Antibiotic Production
The stock culture of P. brachysporum K481-B101was propagated at 28°C for 3 days on agar slant medium composed of soluble starch 0.5 %, glucose 0.5 %, meat extract 0.1 %, yeast extract 0.1 %, NZ-case 0.2%, NaCl 0.2%, CaCO3 0.1% and agar 1.6% (pH 7.0). A well grown agar slant was used to inoculate the vegetative mediumconsisting of corn starch 2%, soybean meal 3%, MgSO4* 7H2O 0.3% and CaCO3 1 % (pH 7.0, before sterilization).
After incubation at 28°C for 3 days on a rotary shaker (250 rpm), 5 ml of the growth was transferred into a 500-ml Erlenmeyer flask containing 100 ml of the production mediumhaving the same composition as the vegetative medium. The antibiotic production was monitored by the paper-disk agar diffusion method using Candida albicans A9540 as the test organism. The fermentation was continued for 4 days at 28°C on a rotary shaker until the antibiotic production reached a maximumof 100^g/ml.
The fermentation was also carried out in stir-jar fermentors. A 500-ml portion of the seed culture obtained by flask fermentation was used to inoculate 10 liters of the production medium in 20-liter vessels. The fermentation was carried out at 28°C with agitation at 250rpm and aeration at 10 liters per minute. The antibiotic production reached a maximumof 150^g/ml after 40 hours' * Glidobactins A, B and C are originally celled as BU-2867T A, B and C or BMY-28119, -28262 and -28120, respectively. OCT. 1988 fermentation.
Isolation and Purification
The whole fermentation broth (48 liters) was centrifuged with the aid of a Sharpies centrifuge. The mycerial cake was homogenized with 7 liters of methanol and the mixture stirred for 1 hour. After removal of the insolubles by filtration, the methanol extract was evaporated to an aqueous solution which was combined with the broth filtrate and extracted with butanol (24 liters). The extract was concentrated to 0.5 liter which was poured into «-hexane (3.5 liters) under vigorous stirring to precipitate the crude antibiotic (41 g). This solid was chromatographed on a column of silica gel (Wakogel C-200, 760 ml) eluting with ethyl acetate and increasing amounts of methanol (0~50%). The bioactivity eluted was detected by the paper-disc assay using C. albicans A9540 as the test organism. The active fractions were combined and evaporated to yield pale yellow powder of glidobactin complex (13 g). A 200-mgportion of this solid was chromatographed on a reverse-phase silica gel column (Merck Kieselgel 60 silanized, 100 ml) using ethanol -water (3 :7 to 5 : 5) as eluants. The eluate was monitored by antifungal bioassay and TLC(silanized, ethanol -water (55 : 45)). The first active fractions were combined and evaporated under reduced pressure to afford pure white solid of glidobactin A (61 mg). This solid was crystallized from aqueous methanol to deposit colorless needles (34 mg). Evaporation of the second and third active fractions yielded glidobactins B (1 mg) and C (ll mg), respectively. Glidobactin C was crystallized from methanol as fine needles. Repetition of the above reverse-phase silica gel chromatography afforded a total of 3.9 g of glidobactin A, 44 mg of glidobactin B and 342 mg of glidobactin C.
Physico-chemical Properties
Glidobactins A and C were obtained as colorless needles while glidobactin B was isolated as white crystalline powder. The three components displayed very similar physico-chemical and spectroscopic properties but they were distinguished from each other by the TLCand the HPLCsystems as described in Table 1 «-hexane and water. They gave a positive response to Rydon-Smith reagent and colored upon spray of iodine or sulfuric acid on TLCplate. They were negative to ninhydrin, Sakaguchi, anthrone and Dragendorff reaction. Glidobactins A, B and C were analyzed for C27H44N4O6, C29H46N4O6 and C29H48N4O6,respectively, by the mass spectrometry and microanalyses. The UVspectra of the three components exhibited a single maximumat 261 nm in methanol which did not shift in acidic nor alkaline solution. The IR spectrum of glidobactin A in KBr (Fig. 1) showed strong amide bands at around 1630 and 1540cm"1 and OHand/or NHabsorption at 3300cm"1. Its XHNMRspectrum (Fig. 2) 1.24, d) were also observed in the spectrum. The 13C NMRspectrum of glidobactin A (Fig. 3) showed more than 22 carbon signals including four carbonyl carbons, six olefinic carbons and three methyl carbons. Glidobactins B and C showed the 13C NMRspectra very similar to that of glidobactin A except the presence of two more oleflnic carbons in glidobactin B and two more methylene carbons in glidobactin C than in glidobactin A. Antimicrobial Activity The MICs of glidobactins A, B and C were determined for various microorganisms by the serial agar dilution method. Nutrient agar (Eiken) was used for bacteria and Sabouraud dextrose agar (Difco) for fungi. The inoculum size was adjusted to 104 cfu/ml for bacteria and 105~107 cfu/ml for fungi. Glidobactins A, B and C did not inhibit the growth of Gram-positive and Gram-negative bacteria at 50 A«g/ml. The antifungal activities of glidobactin components are shown in Table 2 . Component C showedpotent antifungal activity against clinically important pathogenic fungi such as Candida albicans, Cryptococcus neoformans, Aspergillus fumigatus, Trichophyton mentagrophytes and Mucor spinosus. Components A and B were somewhatless active than componentC, but their antifungal Medium:Sabouraud dextrose agar. Table 3 . Effects on the cell growth and macromolecular biosynthesis. spectra were similar to that of the latter. Antitumor Activity Effects on the cell growth and macromolecular biosynthesis were determined according to the published method4>5). As shown in Table 3 , glidobactins A, B and C exhibited strong cytotoxicity against Bl6 and HCT-116cells and inhibited protein synthesis. The in vivo antitumor activity of glidobactin was determined in female CDF1and male BDFX mice. Lymphocytic leukemia P388 (CDFi and BDFXmice) and lymphoid leukemia LI210 (BDFX mice) were inoculated by intraperitoneal injection of 0.4 ml of diluted ascitic fluid containing 106 and 105 cells per mouse, respectively. Melanotic melanoma B16 (BDFXmice) was implanted in 0.5 ml of a 10%-tumor brei intraperitoneally.
Test materials were dissolved in 0.9 % saline containing 10% dimethyl sulfoxide and graded doses of them were administered to the mice intraperitoneally 24 hours after tumor implantation. Either olivomycin or mitomycinC was comparatively tested as a reference compound in the experiments. Glidobactins A, B and C showed antitumor activity against P388 Ratio of median survival time of test and control mice (CDFl5 n=4). Schedule 1 : Treatments given once a day on days 1, 4 and 7. Values^125 % indicate significant antitumor effect. Ratio of median survival time of test and control mice (BDFl9 n= \2). Schedule 2: Treatments given once daily for 9 days. Values^125 %indicate significant antitumor effect.
leukemia by the treatment schedule 1 (once a day on days 1, 4 and 7) by the following order in terms of minimumeffective dose: A=C>B (Table 4) . As shown in Table 5 , glidobactins A and C were highly active against P388 leukemia by the treatment schedule 2 (once daily on days 1 to 9). However, glidobactin A showed moderate activity against LI210 leukemia and B16 melanoma. Whenthe acute toxicity of glidobac- (Fig. 4) . Glidobactins A, B and C exhibited broad antifungal activity in vitro but their in vivo antifungal activity was marginal. They showed strong cytotoxicity against various tumor cells and prolonged the life span of mice implanted with P388 leukemia.
